Aravive Inc.

3.91+0.1000+2.62%Vol 64.14K1Y Perf -35.56%
Sep 15th, 2021 16:00 DELAYED
BID3.86 ASK3.90
Open3.85 Previous Close3.81
Pre-Market- After-Market-
 - -%  - -
Target Price
22.00 
Analyst Rating
Strong Buy 1.00
Potential %
462.66 
Finscreener Ranking
★★★★★     63.11
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
★★★★     55.59
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
★★★+     56.38
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
4.43 
Earnings Rating
Strong Buy
Market Cap80.99M 
Earnings Date
4th Nov 2021
Alpha-0.04 Standard Deviation0.30
Beta3.08 

Today's Price Range

3.793.94

52W Range

3.639.95

5 Year PE Ratio Range

-2.20-1.10

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-1.51%
1 Month
0.51%
3 Months
-24.95%
6 Months
-48.75%
1 Year
-35.56%
3 Years
-55.06%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ARAV3.910.10002.62
AAPL149.030.91000.61
GOOG2 904.1236.00001.26
MSFT304.825.03001.68
XOM56.421.84003.37
WFC46.640.59001.28
JNJ165.420.62000.38
FB373.92-2.6100-0.69
GE102.161.78001.77
JPM158.161.09000.69
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.41-0.3514.63
Q01 2021-0.45-0.442.22
Q04 2020-0.52-0.2551.92
Q03 2020-0.42-0.66-57.14
Q02 2020-0.45-0.3228.89
Q01 2020-0.34-0.53-55.88
Q04 2019-0.53-0.3533.96
Q03 2019-0.50-0.54-8.00
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.4210.64Positive
12/2021 QR-0.477.84Positive
12/2021 FY-1.762.22Positive
12/2022 FY-2.15-11.40Negative
Next Report Date4th Nov 2021
Estimated EPS Next Report-0.42
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume64.14K
Shares Outstanding20.71M
Shares Float14.90M
Trades Count606
Dollar Volume823.72K
Avg. Volume326.54K
Avg. Weekly Volume68.85K
Avg. Monthly Volume76.75K
Avg. Quarterly Volume564.60K

Aravive Inc. (NASDAQ: ARAV) stock closed at 3.91 per share at the end of the most recent trading day (a 2.62% change compared to the prior day closing price) with a volume of 64.14K shares and market capitalization of 80.99M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 17 people. Aravive Inc. CEO is Gail McIntyre.

The one-year performance of Aravive Inc. stock is -35.56%, while year-to-date (YTD) performance is -30.67%. ARAV stock has a five-year performance of %. Its 52-week range is between 3.63 and 9.95, which gives ARAV stock a 52-week price range ratio of 4.43%

Aravive Inc. currently has a PE ratio of -2.30, a price-to-book (PB) ratio of 1.28, a price-to-sale (PS) ratio of 8.35, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -37.23%, a ROC of -42.60% and a ROE of -47.03%. The company’s profit margin is -%, its EBITDA margin is -268.10%, and its revenue ttm is $9.73 Million , which makes it $0.47 revenue per share.

Of the last four earnings reports from Aravive Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.42 for the next earnings report. Aravive Inc.’s next earnings report date is 04th Nov 2021.

The consensus rating of Wall Street analysts for Aravive Inc. is Strong Buy (1), with a target price of $22, which is +462.66% compared to the current price. The earnings rating for Aravive Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aravive Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aravive Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.35, ATR14 : 0.21, CCI20 : -86.38, Chaikin Money Flow : -0.06, MACD : -0.09, Money Flow Index : 45.55, ROC : -4.87, RSI : 42.00, STOCH (14,3) : 22.22, STOCH RSI : 0.61, UO : 36.52, Williams %R : -77.78), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aravive Inc. in the last 12-months were: Amato Giaccia (Option Excercise at a value of $725), Gail McIntyre (Buy at a value of $5 345), Vinay Shah (Buy at a value of $5 310)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Aravive Inc.

Aravive Inc is a clinical-stage biotechnology company. It focuses on developing therapies that target important survival pathways for both solid tumors as well as hematologic malignancies. The company's lead candidate AVB-500 is developed as a targeted therapy against ovarian cancer.

CEO: Gail McIntyre

Telephone: +1 936 355-1910

Address: 3730 Kirby Drive, Houston 77010, TX, US

Number of employees: 17

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

49%51%

Bearish Bullish

67%33%

News

Stocktwits